Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by AIA Group Ltd

AIA Group Ltd decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,829 shares of the company’s stock after selling 285 shares during the period. AIA Group Ltd’s holdings in Medpace were worth $561,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Daiwa Securities Group Inc. boosted its holdings in shares of Medpace by 213.6% in the 4th quarter. Daiwa Securities Group Inc. now owns 345 shares of the company’s stock valued at $105,000 after buying an additional 235 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Medpace by 2.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock valued at $2,114,000 after purchasing an additional 148 shares during the last quarter. Wealth Alliance raised its position in Medpace by 9.9% in the 4th quarter. Wealth Alliance now owns 1,053 shares of the company’s stock valued at $323,000 after purchasing an additional 95 shares during the last quarter. Suncoast Equity Management purchased a new stake in Medpace in the 4th quarter valued at $412,000. Finally, Strs Ohio raised its position in Medpace by 4.4% in the 4th quarter. Strs Ohio now owns 4,501 shares of the company’s stock valued at $1,379,000 after purchasing an additional 189 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of Medpace stock opened at $372.00 on Friday. The company has a market cap of $11.53 billion, a P/E ratio of 41.89, a PEG ratio of 1.98 and a beta of 1.38. Medpace Holdings, Inc. has a one year low of $185.43 and a one year high of $419.42. The firm has a fifty day moving average of $395.78 and a two-hundred day moving average of $319.96.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 12th. The company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.22 by $0.24. The company had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. Medpace had a net margin of 15.00% and a return on equity of 63.98%. Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.12 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 10.53 earnings per share for the current year.

Insiders Place Their Bets

In other Medpace news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Ashley M. Keating sold 250 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the transaction, the director now directly owns 250 shares of the company’s stock, valued at approximately $102,467.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The disclosure for this sale can be found here. In the last quarter, insiders sold 189,340 shares of company stock worth $76,651,647. 20.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on MEDP shares. Robert W. Baird upped their price target on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research report on Wednesday, February 14th. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 23rd. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and upped their price target for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target for the company. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Medpace currently has an average rating of “Moderate Buy” and an average target price of $382.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.